Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges
The mammalian (or mechanistic) target of rapamycin (mTOR) pathway has a key role in the regulation of a variety of biological processes pivotal for cellular life, aging, and death. Impaired activity of mTOR complexes (mTORC1/mTORC2), particularly mTORC1 overactivation, has been implicated in a pleth...
Main Authors: | Sofia D. Viana, Flávio Reis, Rui Alves |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2018-01-01
|
Series: | Oxidative Medicine and Cellular Longevity |
Online Access: | http://dx.doi.org/10.1155/2018/3693625 |
Similar Items
-
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
by: Zhilin Zou, et al.
Published: (2020-03-01) -
Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex
by: Filipe Palavra, et al.
Published: (2017-01-01) -
mTOR signaling pathway and mTOR inhibitors in the treatment of cancer
by: Mehmet Küçüköner, et al.
Published: (2013-03-01) -
mTOR Inhibitors in Advanced Biliary Tract Cancers
by: Chao-En Wu, et al.
Published: (2019-01-01) -
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
by: Tian Tian, et al.
Published: (2019-02-01)